Speaker Profile
CEO, Y-Trap
Biography
Rishi leads the discovery and development of multifunctional fusion proteins for cancer immunotherapy at Y-Trap. He co-invented Y-Trap's versatile engineering platform to develop a portfolio of therapeutics designed to counteract the determinants of tumor-induced immune tolerance.Previously, Rishi drove the computational design of broad-spectrum vaccines at Centivax. Before that, he started and built the AIML team at Herophilus, where he led the application of AI methods to uncover novel multi-modal phenotypes for drug discovery in neuropsychiatric and neurodegenerative diseases. Rishi studied computer science at Stanford with a focus in AI applied to biophysics (protein structure prediction, protein engineering).
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025AI for Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies to explore the transformative role of artificial intelligence in accelerating the discovery, development, and optimization of novel therapeutic modalities. From predictive algorithms for drug efficacy to real-time analysis in clinical trials, AI is revolutionizing the way we approach emerging therapies, including RNA-based treatments, gene editing, and personalized medicine. Industry leaders and experts will discuss AI-driven advancements, collaborative frameworks, and the challenges of integrating cutting-edge technologies into therapeutic innovation. Join us for an in-depth look at how AI is shaping the future of breakthrough therapeutics.
